Old Web
English
Sign In
Acemap
>
Paper
>
PET2-driven de-escalation therapy in 64 high-risk Hodgkin Lymphoma patients treated with escalated BEACOPP
PET2-driven de-escalation therapy in 64 high-risk Hodgkin Lymphoma patients treated with escalated BEACOPP
2015
Benedicte Deau
Patricia Franchi
Josette Brière
Jessica Ohnona
Jerome Tamburini
Catherine Thieblemont
Pauline Brice
Keywords:
Lymphoma
Etoposide
Medicine
BEACOPP
Immunology
Cancer research
Doxorubicin
De-escalation
Prednisone
Medical physics
Procarbazine
Cyclophosphamide
Oncology
Internal medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
10
References
6
Citations
NaN
KQI
[]